# 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis

> **NCT00115089** · PHASE2 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 375 (—)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** R926112
- **DRUG:** Beclomethasone dipropionate

## Key facts

- **NCT ID:** NCT00115089
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 375 (—)
- **Last updated:** 2005-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115089, "7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00115089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*